Combination of Local Therapy and Target Therapy for Brain Metastases With EGFR Mutation

NCT ID: NCT05616377

Last Updated: 2022-11-15

Basic Information

• Recruitment Status: UNKNOWN
• Total Enrollment: 2000 participants
• Study Classification: OBSERVATIONAL
• Study Start Date: 2022-11-20
• Study Completion Date: 2024-11-20

Brief Summary

The goal of this observational study is to learn about the survival benefit of local therapy combination with target therapy in lung cancer brain metastases with EGFR mutation. The main questions it aims to answer are:

• Is local therapy performed before or after target therapy would provide survival benefit ?
• What kind of local therapy combining with target therapy would provide survival benefit, neurosurgical resection or radiotherapy?

Conditions

Brain Metastases

Study Design

• Observational Model Type: CASE_CONTROL
• Study Time Perspective: RETROSPECTIVE

Study Groups

target therapy + local therapy group vs target therapy alone group

Surgery or Radiotherapy

Intervention Type: OTHER

Participants who underwent target therapy and surgery or radiotherapy were divided into target therapy + local therapy group. Participants who underwent target therapy alone were divided into target therapy alone group

local therapy before target therapy group vs local therapy after target therapy group

before or after target therapy

Intervention Type: OTHER

Participants who underwent surgery or radiotherapy before target therapy were divided into local therapy before target therapy group. Participants who underwent surgery or radiotherapy after target therapy were divided into local therapy after target therapy group.

Interventions

Surgery or Radiotherapy

Participants who underwent target therapy and surgery or radiotherapy were divided into target therapy + local therapy group. Participants who underwent target therapy alone were divided into target therapy alone group

Intervention Type: OTHER

before or after target therapy

Participants who underwent surgery or radiotherapy before target therapy were divided into local therapy before target therapy group. Participants who underwent surgery or radiotherapy after target therapy were divided into local therapy after target therapy group.

Intervention Type: OTHER

Eligibility Criteria

Inclusion Criteria

1. Evidence of pathological diagnosis of primary tumor.

2. Brain metastases confirmed by enhanced magnetic resonance imaging.

3. Gene test indicated that EGFR mutation.

4. Complete clinical information.

Exclusion Criteria

1. If surgical treatment is accepted, the surgical treatment is not tumor resection, but ventricle puncture, biopsy and other non-tumor reducing surgery.

2. Patients with 2 or more types of tumors.

3. Incomplete clinical information.

• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Sun Yat-sen University

OTHER

Sponsor Role: lead

Responsible Party

Yonggao Mou

Department of Neurosurgery

Responsibility Role: PRINCIPAL_INVESTIGATOR

Central Contacts

Lun Liang, PHD

Role: CONTACT

lianglun@sysucc.org.cn

18277186779

Other Identifiers

EGFR+BM

Identifier Type: -

Identifier Source: org_study_id